Premium
Disease progression and comorbidities in lipedema patients: A 10‐year retrospective analysis
Author(s) -
Ghods Mojtaba,
Georgiou Iakovos,
Schmidt Jeremias,
Kruppa Philipp
Publication year - 2020
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.14534
Subject(s) - medicine , liposuction , dyslipidemia , retrospective cohort study , disease , comorbidity , diabetes mellitus , metabolic syndrome , depression (economics) , body mass index , obesity , surgery , pediatrics , economics , macroeconomics , endocrinology
Abstract Multiple associated comorbidities have been described for lipedema patients. Disease diagnosis still remains challenging in many cases and is frequently delayed. The purpose of this study was to determine the most common comorbidities in lipedema patients and the impact of surgical treatment onto disease progression. A retrospective assessment of disease‐related epidemiologic data was performed for patients who underwent liposuction between July 2009 and July 2019 in a specialized clinic for lipedema surgery. All patients received a standardized questionnaire regarding the clinical history and changes of lipedema‐associated symptoms and comorbidities after surgery. 106 patients who underwent a total of 298 liposuction procedures were included in this study after returning the questionnaire fully filled‐in. Multiple comorbidities were observed in the assessed collective. The prevalence for obesity, hypothyroidism, migraine, and depression were markedly increased in relation to comparable nonlipedema populations. Despite a median body mass index (BMI) of 31.6 kg/m 2 (IQR 26.4‐38.8), unexpected low prevalence of diabetes (5%) and dyslipidemia (7%) was found. Diagnosis and initiation of guideline‐appropriate treatment were delayed by years in many patients. After surgical treatment (medium follow‐up 20 months, IQR 11‐42), a significant reduction of lipedema‐associated symptoms was demonstrated. Lipedema occurs with a diversity of associated comorbidities. Therefore, on the basis of available data, the authors suggest the necessity of a multimodal therapy concept for a comprehensive and holistic treatment. Despite a commonly increased BMI, lipedema patients appear to have an advantageous metabolic risk profile.